T
4.72
0.06 (1.29%)
| 前收盘价格 | 4.66 |
| 收盘价格 | 4.65 |
| 成交量 | 1,303,874 |
| 平均成交量 (3个月) | 3,255,008 |
| 市值 | 1,292,899,328 |
| 价格/销量 (P/S) | 212.62 |
| 股市价格/股市净资产 (P/B) | 5.64 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业利益率 (TTM) | -930.54% |
| 稀释每股收益 (EPS TTM) | -0.340 |
| 季度收入增长率 (YOY) | -32.50% |
| 总债务/股东权益 (D/E MRQ) | 111.93% |
| 流动比率 (MRQ) | 5.35 |
| 营业现金流 (OCF TTM) | -83.45 M |
| 杠杆自由现金流 (LFCF TTM) | -52.28 M |
| 资产报酬率 (ROA TTM) | -35.91% |
| 股东权益报酬率 (ROE TTM) | -159.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Taysha Gene Therapies, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
-0.9
| 分析师共识 | 2.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.90 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 12.11% |
| 机构持股比例 | 67.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 21,700,000 |
| Siren, L.L.C. | 30 Sep 2025 | 11,014,737 |
| Octagon Capital Advisors Lp | 30 Sep 2025 | 9,067,500 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 5,500,000 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 5,386,000 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 5,293,879 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 12.00 (Chardan Capital, 154.24%) | 购买 |
| 中 | 11.00 (133.05%) | |
| 低 | 8.00 (Citizens, 69.49%) | 购买 |
| 平均值 | 10.33 (118.86%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 4.73 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Chardan Capital | 06 Jan 2026 | 12.00 (154.24%) | 购买 | 5.26 |
| 05 Nov 2025 | 12.00 (154.24%) | 购买 | 4.03 | |
| Wells Fargo | 05 Jan 2026 | 11.00 (133.05%) | 购买 | 4.89 |
| Citizens | 05 Nov 2025 | 8.00 (69.49%) | 购买 | 4.03 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ALAM KAMRAN | - | 4.69 | -102,817 | -480,558 |
| NAGENDRAN SUKUMAR | - | 4.69 | -116,050 | -542,408 |
| NOLAN SEAN P. | - | 4.69 | -178,101 | -832,429 |
| 累积净数量 | -396,968 | |||
| 累积净值 ($) | -1,855,396 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 4.69 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ALAM KAMRAN | 职员 | 26 Jan 2026 | 卖 (-) | 23,849 | 4.72 | 112,567 |
| NOLAN SEAN P. | 职员 | 26 Jan 2026 | 卖 (-) | 41,312 | 4.72 | 194,993 |
| NAGENDRAN SUKUMAR | 职员 | 26 Jan 2026 | 卖 (-) | 26,918 | 4.72 | 127,053 |
| ALAM KAMRAN | 职员 | 23 Jan 2026 | 卖 (-) | 78,968 | 4.66 | 367,991 |
| NOLAN SEAN P. | 职员 | 23 Jan 2026 | 卖 (-) | 136,789 | 4.66 | 637,437 |
| NAGENDRAN SUKUMAR | 职员 | 23 Jan 2026 | 卖 (-) | 89,132 | 4.66 | 415,355 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合